Demeunynck M, Charmantray F, Martelli A
LEDSS, Laboratoire de Chimie Bioorganique, UMR CNRS 5616, Universite Joseph Fourier, BP 53, 38041 Grenoble, France.
Curr Pharm Des. 2001 Nov;7(17):1703-24. doi: 10.2174/1381612013397131.
DNA is considered as one of the main targets for anticancer drug design. The planar structure of acridines confers to the molecules the ability to bind DNA by intercalation and therefore to interfere with metabolic processes. A large number of natural alkaloids and synthetic acridine derivatives have been tested as anticancer agents. So far, a few molecules have entered clinical trials and have been approved for chemotherapy. The mechanisms of action are not fully understood. Cytotoxicity may be related to potent enzyme inhibition. Topoisomerase and telomerase activities may be strongly affected by acridines. The affinity of acridines for DNA has also been used to design new active compounds in which a DNA modifying group is tethered to the acridine nucleus. Acridine derivatives display other pharmacological properties such as antibacterial and antimalarial activities. They are also tested for Alzheimer's disease.
DNA被认为是抗癌药物设计的主要靶点之一。吖啶的平面结构赋予分子通过嵌入作用结合DNA的能力,从而干扰代谢过程。大量天然生物碱和合成吖啶衍生物已作为抗癌剂进行测试。到目前为止,一些分子已进入临床试验并已被批准用于化疗。其作用机制尚未完全了解。细胞毒性可能与强效酶抑制有关。吖啶可能会强烈影响拓扑异构酶和端粒酶的活性。吖啶对DNA的亲和力也已被用于设计新的活性化合物,其中一个DNA修饰基团与吖啶核相连。吖啶衍生物还具有其他药理特性,如抗菌和抗疟活性。它们也正在针对阿尔茨海默病进行测试。